tbuckley/cabot-search huggingface dataset:
The role of RANK-signaling in tumor cell proliferation and migration in pancreatic adenocarcinoma.
Authors: Alexander T. El Gammal, Natalie Sander, Aljonna Foelster, Leonie Konczalla, Henrike Friedenberger, Cenap Guengoer, Gerrit Wolters-Eisfeld, Rusudan Sreseli, Bianca T. Hofmann, Jakob Robert Izbicki, Maximillian Bockhorn, Daniel R. Perez
Journal: Journal of Clinical Oncology (2014)

e15193 Background: Receptor Activator of Nuclear Factor kappa-B (RANK) and its ligand (RANKL) are well-described players in osteometabolism, immunomodulation and carcinogenesis. Their roles in human Pancreatic Ductal Adenocarcinoma (PDAC) have not been described so far. Methods: Protein expression was analyzed via Westernblots and qrtPCR. A lentivrial si-RNA mediated knockdown of RANK was performed in two pancreatic carcinoma cell lines BxPC3(BxPc3 RANK-KO) and Panc-1(Panc-1RANK-KO). Proliferation rates of cell lines were determined by established MTT assays. Migration rates were measured by transwell migration assays. Destribution of RANK and RANKL expression was analyzed via immunohistochemical staining (IHC) in malignant and precancerous tissue specimes of 34 PDAC patients. Results: RANKL, RANK, and Cyclooxygenase2 (COX2) were expressed in PDAC cell lines on mRNA- and protein level. In contrast to BxPC3 , Panc-1 showed high levels of RANK but low levels of COX2 expression. COX2 is inducible by soluble RANKL (sRANKL) stimulation in Panc-1 and BxPC3 cells (BxPC3>Panc-1). BxPC3 cells increased proliferation rate significantly compared to a non-malignant reference pancreas cell line (HPDE) after sRANKL stimulation. Panc-1RANK-KO and BxPc3 RANK-KO cells did not respond to sRANKL stimulation. Migration rate of BxPC3 cells decreased after sRANKL stimulation. IHC staining of PDAC specimens showed positivity for RANKL and RANK. RANK showed signs of suborganelle positive staining; in contrast, it was expressed membranously in pancreatic intraepithelial neoplasia(PANIN). RANKL showed positivity in Fibroblasts and PDAC tissue in IHC. Conclusions: We provide evidence for RANK- and RANKL expression in PDAC and the stromal compartment, respectively. The RANK-signaling pathway becomes activated upon RANKL stimulation, resulting in target gene expression, e.g. COX2. RANK-signaling seems to be a key player in COX2 dependent proliferation and migration in human PDAC cells. Also, RANK is cytoplasmic expressed in human PDAC tissue and membranous expressed in PANINs; thus RANK might be involved in carcinogenesis . RANKL shows signs of expression in PDAC cells and fibroblast indicating tumor-stroma interaction.
ASSOCIATION OF ACADEMIC YEAR-END CHANGEOVER WITH SURVIVAL RATES AFTER IN-HOSPITAL CARDIAC ARREST: AN EXAMINATION OF THE “JULY EFFECT”
Authors: Tanush Gupta, Sahil Khera, Dhaval Kolte, Pedro Villablanca, Wilbert Aronow, Howard Cooper, Gregg Fonarow, Deepak Bhatt, Julio Panza, Ernest Monrad, Mark Menegus, Mario Garcia
Journal: Journal of the American College of Cardiology (2017)
WHAT KIND OF MESENCHYMAL STEM CELL IS PROMISING IN THE PREVENTION OF PULMONARY ARTERIAL HYPERTENSION IN A MURINE MODEL?
Authors: Seungbum Choi, Seyeon Oh, Sehyun Chae, Jeongsik Moon, Kyung-Hee Kim, Bo Ram Choi, Myeong Gun Kim, Sihun Kim, Minsu Kim, Youngwoo Jang, Daehee Hwang, Kyunghee Byun, Wook-Jin Chung
Journal: Journal of the American College of Cardiology (2017)
Albumin component of nab-paclitaxel and skin toxicities in Chinese breast cancer patients.
Authors: Xi-Chun Hu, Lichen Tang, Biyun Wang, Si Sun, Jian Zhang, Zhen Jia, Yunhua Lu, Genhong Di, Shao Zhimin
Journal: Journal of Clinical Oncology (2012)

e11567 Background: This phase II study was to explore the efficacy and safety of weekly nab-paclitaxel and cisplatin combinationin Chinese advanced breast cancer (ABC) patients. While all other safety profiles were similar and expected based on published clinical trial results conducted in Western patients, the incidence of skin rash was unexpectedly higher. Methods: Nab-paclitaxel(125 mg/m 2 ) was administered on days 1, 8, 15, followed by cisplatin (75 mg/m 2 ) on day 1 every 28 day cycle until disease progression, intolerable toxicities or the maximum of 6 cycles. Patients who received at least one injection of the study drug were included in this analysis of the incidence of skin rash among Chinese patients. Toxicity was graded using the CTCAE4.0. The incidences of skin toxicity with conventional- and nab-paclitaxel were obtained from published trial results in both Chinese and Western patients. Results: 73 patients enrolled were qualified to be analyzed, and a total of 384 cycles were administered before the datalock on Oct 1st, 2011. Rash was presented in 27 patients (37.0%). The most common sites involved were face (14/27), neck (14/27), limbs (18/27) and frictional parts of the trunk (10/27). Macular and papular rash with pruritus commonly occurred 2 (1-7) days after the first day of chemotherapy. Only one patient developed Grade 3 skin toxicity with generalized erythroderma and disfigurement of the face requiring dose reduction. The rash gradually regressed 2 (1-10) days after antihistamines using and pigmentation remained in 13/27 cases. The incidence rate of skin toxicity was significantly higher in Chinese patients than Western counterparts (P&lt;0.0001), while no difference was found with conventional paclitaxel. Conclusions: A higher rate of skin toxicity occurred in Chinese breast cancer patients treated with weekly nab-paclitaxel comparing to Western patients. The albumin component of nab-paclitaxel maybe the cause of the skin disorder. [Table: see text]
Regulation of B-Cell Receptor Signalling By the Tumour Microenvironment in Chronic Lymphocytic Leukemia (CLL) and Its Impact on Adhesion and miRNA Expression
Authors: Matthew D Blunt, Rachel Dobson, Lindsay D Smith, Jonathan C. Strefford, Pamela B. Conley, Anjali Pandey, Andrew J Davies, Peter M Johnson, Graham Packham, Freda K Stevenson, Francesco Forconi, Greg P Coffey, Andrew J Steele
Journal: Blood (2016)
The antihelmenthic phosphate niclosamide impedes renal fibrosis by inhibiting homeodomain-interacting protein kinase 2 expression
Authors: Xiaoyan Chang, Xin Zhen, Jixing Liu, Xiaomei Ren, Zheng Hu, Zhanmei Zhou, Fengxin Zhu, Ke Ding, Jing Nie
Journal: Kidney International (2017)
Does H<sub>2</sub> Alter Mitochondrial Bioenergetics via GHS-R1α Activation?
Authors: Sergej M. Ostojic
Journal: Theranostics (2017)

More than 400 original articles have been published from 2007 onwards evaluating therapeutic potential of molecular hydrogen (H2), the youngest member of medical gases family with selective anti-oxidative properties.However, recent studies suggest that H2 may tackle other mitochondrial processes besides oxidative stress, including metabolic pathways that drive cellular energy.
PREDICTIVE RISK STRATIFICATION USING HEART AND THROMBOLYSIS IN MYOCARDIAL INFARCTION SCORES IN LOW RISK CHEST PAIN PATIENTS: AN URBAN COMMUNITY BASED HOSPITAL STUDY
Authors: Reshma Reddy Golamari, Sandhya Vunnam, Smitha Moparthi, Neethi Venkatappa, Wei Yang, Eddy Mizrahi, Priyanka Bhattacharya
Journal: Journal of the American College of Cardiology (2017)
International validation of a nomogram for predicting disease-specific survival following an R0 resection for gastric cancer in a multicenter patient population
Authors: M. W. Kattan, K. Peeters, C. Van de Velde, H. Hartgrink, E. Klein Kranenbarg, M. Brennan
Journal: Journal of Clinical Oncology (2004)

6050 Background: We previously published a statistical model for predicting an individual patient's probability for disease-specific survival for 5 and 9 years following an r0 resection for gastric cancer. This tool was based on a single institution experience involving 1039 patients treated from 1985 to 2002. The purpose of this study was to assess the validity of this prediction tool when applied to patients treated at different institutions. Methods: Between 1989 and 1993, 633 eligible patients underwent a r0 resection in the Dutch Gastric Cancer trial that was conducted in 80 Dutch hospitals and compared D1 with D2 lymph node dissection. After excluding those with missing values, 285 patients had values for all nomogram predictor variables, AJCC stage, and disease-specific follow-up. For each of these patients, the nomogram 5 and 9 year disease-specific survival probabilities were computed and compared with the AJCC stage on the basis of discrimination ability, as measured by the concordance index. Results: To date, 174 of the 285 patients have died of disease. The concordance index for the nomogram (CI=0.0.77) was superior to that of the AJCC stage (CI=0.75, P<0.001). There was considerable variation in risk within many of the AJCC stages. Calibration plots suggested that predicted probabilities from the nomogram corresponded closely to actual disease-specific survival observed in the validation dataset estimated by the Kaplan-Meier method. Conclusions: To date, 174 of the 285 patients have died of disease. The concordance index for the nomogram (CI=0.0.77) was superior to that of the AJCC stage (CI=0.75, P<0.001). There was considerable variation in risk within many of the AJCC stages. Calibration plots suggested that predicted probabilities from the nomogram corresponded closely to actual disease-specific survival observed in the validation dataset estimated by the Kaplan-Meier method. Additional data and graphics are found in: J Clin Oncol 2003: 21(19): 3647–3650. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Sanofi-Synthelabo Aventis
SUBCUTANEOUS IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR PLACEMENT IN A PATIENT WITH A PREEXISTING TRANSVENOUS ICD: A CASE FOR DEFIBRILLATOR THRESHOLD TESTING?
Authors: Mohammad-Ali Jazayeri, JoAnn Bartos, Ted Tabbert, Mohammad-Reza Jazayeri
Journal: Journal of the American College of Cardiology (2017)
Adjuvant UK: Validation of a UK prognostic model for early breast cancer
Authors: G. Wishart, D. Greenberg, J. Rashbass, P. Ravdin, G. Lawrence, C. Caldas, P. Pharoah
Journal: Journal of Clinical Oncology (2009)

11086 Background: To develop and validate a prognostication model to predict overall survival for women treated for early breast cancer in the UK based on cancer registry data. The main advantages are that unlike SEER, this dataset includes accurate information on mode of detection as well as systemic therapy. Methods: Using the Eastern Cancer Registration &amp; Information Centre (ECRIC) dataset, information was collated for 5,818 women diagnosed with invasive breast cancer in East Anglia from 1999–2003. All patients underwent surgery, had records of pathological staging (tumour size, grade, lymph node status, ER status) and systemic treatment (chemotherapy, hormone therapy, both), mode of detection (screen-detected, symptomatic) and were followed up to December 2007. A model was derived from these data using Cox proportional hazards and this was subsequently validated in an external dataset of 5,468 patients from the West Midlands Cancer Intelligence Unit (WMCIU). Validation was performed by comparing (a) observed and predicted mortality - overall and by risk group decile - and (b) receiver operating characteristic (ROC) curves in both ECRIC &amp; WMCIU datasets. Results: ECRIC dataset: Observed/predicted deaths were: 2 years (262/267), 5 years (868/867), 8 years (1108/1093). Area under ROC curve was 0.800WMCIU dataset: Observed/predicted deaths were: 2 years (317/298), 5 years (862/919), 8 years (955/999). Area under ROC curve was 0.783. The model and validation worked equally well at all time points (2, 5, 8 years) and in all risk group deciles. In the validation dataset the observed and predicted 8-year OS was within 1% (17.5% versus 18.3%). There was no significant statistical difference between the ROC curves (X 2 = 2.35, P=.12) for prediction at 8 years in ECRIC and WMCIU data. Conclusions: We have developed a prognostication model for early breast cancer based on data from a UK cancer registry and validated the model using data from another UK registry. The model was well calibrated and provides a high degree of discrimination. This model will underpin the first web-based prognostication and treatment benefit tool for early breast cancer in the UK (Adjuvant UK). No significant financial relationships to disclose.
COMPARISON OF NEOINTIMAL APPEARANCE ASSESSED BY OPTICAL COHERENCE TOMOGRAPHY BETWEEN BARE-METAL STENTS AND SIROLIMUS-ELUTING STENTS BEYOND 10 YEARS FROM IMPLANTATION
Authors: Takayuki Niida, Taishi Yonetsu, Tadashi Murai, Yoshihisa Kanaji, Eisuke Usui, Masahiro Hoshino, Masao Yamaguchi, Masahiro Hada, Sadamitsu Ichijo, Rikuta Hamaya, Yoshinori Kanno, Tsunekazu Kakuta
Journal: Journal of the American College of Cardiology (2017)
ASSOCIATIONS OF HIV RELATED FACTORS WITH ADJUDICATED HEART FAILURE (HF) IN AN ELECTRONIC COHORT OF HIV-INFECTED (HIV+) PERSONS
Authors: Alexandra Steverson, Anna E. Pawlowski, Daniel Schneider, Prasanth Nannapaneni, Jes Sanders, Chad J. Achenbach, Sanjiv Shah, Donald Lloyd-Jones, Matthew Feinstein
Journal: Journal of the American College of Cardiology (2017)
Humoral immune-response to naturally occurring STn in metastatic breast cancer patients (MBC pts) treated with STn-KLH vaccine
Authors: N. K. Ibrahim, J. Murray, J. Parker, L. Finke, D. Miles
Journal: Journal of Clinical Oncology (2004)

2547 Background: Theratope is an investigational therapeutic cancer vaccine consisting of a synthetic form of STn conjugated to KLH. Phase III study results showed a trend for increased survival in MBC pts concurrently treated with Theratope (T) and hormone therapy (HT) (38.2mo (T) vs. 30.7mo (control, C), Cox P= 0.07). Methods: MBC pts with no evidence of disease or non-progressive disease following any first-line chemotherapy were eligible for a randomized, controlled, double-blind, multicenter study. Study arms were adjuvant plus T or adjuvant plus KLH (C). All pts received a single IV dose of cyclophosphamide (300mg/m2) 72 hr before vaccine. Primary endpoints were overall survival (OS) and time to progression. Secondary endpoints were humoral (IgG) responses to the KLH (carrier), STn (synthetic monomeric form), and OSM (naturally occurring clustered STn) antigens in MBC pts +/- HT treated with T. IgG was measured using ELISA assays for STn, OSM, and KLH at week-12 of vaccine therapy. Median OS was prospectively assessed as a function of IgG titers. Results: Of a planned accrual of 950 pts, 1030 were enrolled and 1028 randomized to recive adjuvant + T(n=523) or C (n=505). As of September 2003, median duration of follow-up was 22.2 mo. Median titer of anti-OSM IgG was 320 in the T group and 0 in the C group. Median OS was significantly greater in T treated pts who received concurrent HT and who had IgG titers of anti-OSM equal to or higher than the median titer (41.1 vs. 25.4 mo, log-rank p=0.01) (see Table). OS was not influenced by anti-STn or anti-KLH titers, indicating that only titers of the naturally occurring clustered STn antigen are predictive of increased OS. Conclusions: Experimental vaccine trials suggest that the ability to mount an immune response is associated with favorable clinical outcomes. Our data from this large, prospective trial indicate that the magnitude of the immune response to the relevant and specific antigen is most predictive of a favorable clinical outcome. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Biomira, Inc.; EMD Pharmaceuticals Biomira, Inc. Biomira, Inc.; EMD Pharmaceuticals Biomira, Inc.; Merck KGaA
Association of acute phase protein-haptoglobin, and epithelial-mesenchymal transition in buccal cancer.
Authors: Yu-Chieh Su, Ching-Chih Lee, Shih-Kai Hung, Chih-Chia Yu, Szu-Chin Li
Journal: Journal of Clinical Oncology (2012)

e16008 Background: The aim of this study was to determine the influence of inflammation on acute phase protein and epithelial-mesenchymal transition (EMT) in buccal cancer. Methods: Western blotting was carried out to investigate the expression of haptoglobin and epithelial-mesenchymal transition in oral cancer cell lines with or without IL-6 stimulation. We studies patients with buccal cancer patients without distant metastasis at diagnosis. Correlation between cellular haptoglobin, EMT, and clinical characteristics of buccal cancer was analyzed to assess the prognostic value of cellular haptoglobin level and EMT. The relationship of haptoglobin, and EMT expression with survival was assessed using Cox proportional hazard models. Results: Western blotting analysis showed that increased haptoglobin protein was associated with overexpression of vimentin. Under IL-6 stimulation, overexpression of haptoglobin, EMT-associated motile phenotype was noted in OC2 cell lines. Overexpression of haptoglobin was also associated with an increased risk for locoregional recurrence (hazard ratio [HR] 1.04; P=0.011) after adjusting for age, gender, disease site, stage, and treatment modality. Conclusions: Increased cellular expression of haptoglobin is associated with EMT in oral cancer cell lines and this phenomenon could be exaggerated with IL-6. Cellular expression of haptoglobin is related to locoregional recurrence rate in buccal cancer patients.
Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.
Authors: Ashley Ghiaseddin, David A. Reardon, Woody Massey, Alexandra Mannerino, Eric S. Lipp, James E. Herndon, Frances McSherry, Annick Desjardins, Dina M Randazzo, Gordana Vlahovic, Henry S. Friedman, Katherine B Peters
Journal: Journal of Clinical Oncology (2015)

2034 Background: Prognosis for recurrent glioblastoma (GBM) remains dismal with a 9-15% 6-month progression-free survival (PFS). However, the addition of bevacizumab (BEV), a humanized monoclonal IgG1 antibody with effects at human vascular endothelial growth factor, has improved 6-month PFS to 40-50% and median overall survival (OS) to 9.2 months. Vorinostat (VOR) is a small molecule derivative of hydroxamic acid that crosses the blood-brain barrier and has anti-tumor effects directly by inhibition of histone deacetylase and indirectly by anti-angiogenic promotion. In light of VOR's mechanism of action and favorable toxicity/safety profile, we sought to evaluate the efficacy of VOR combined with BEV in recurrent GBM. Methods: A phase II single-center open-label, single arm study was performed to evaluate VOR and BEV in recurrent GBM. Primary endpoint was 6-month PFS. Secondary endpoints were safety/tolerability, radiographic response, PFS, and OS. Major eligibility criteria included age ≥ 18 yrs, KPS ≥ 70 and ≤ 2 prior progressions. Dosing regimen was BEV 10mg/kg IV q2weeks combined with VOR 400mg PO daily for 7 days, then 7 days off in a 28 day cycle. Results: Forty recurrent GBM patients were enrolled. To date, median follow-up time is 13.2 months with 6-month PFS of 30% (95% CI: 16.8%, 44.4%). Median OS is 10.4 months (95% CI: 9.3-13.1 months). Objective radiographic responses included 9 partial responses, 29 stable responses, and 1 radiographic progression with 1 patient not assessed due to early death (sudden death of vascular origin). Most common treatment related grade 2-3 toxicities were lymphopenia (55%), leukopenia (43%), neutropenia (33%) and hypertension (33%). Grade 4 toxicities were leukopenia (3%), neutropenia (3%), sinus bradycardia (3%), and thromboembolic event (3%). Two deaths occurred on study; one due to disease progression and the other was a sudden death of vascular origin. Conclusions: VOR and BEV combination therapy was well-tolerated in recurrent GBM, although it did not improve 6-month PFS when compared to BEV monotherapy. There was a trend towards improved OS in VOR and BEV in comparison to BEV monotherapy. Continued follow-up and research is needed to delineate better the role of chemotherapy in combination with BEV. Clinical trial information: NCT01738646.
Renal Safety after More Than a Decade of Deferasirox Use in Patients with Transfusional Hemosiderosis
Authors: Raffaella Origa, Antonio Piga, Immacolata Tartaglione, Giuseppina Della Corte, Ali El-Ali, Jackie Han, Chiara Castiglioni, Gian Luca Forni
Journal: Blood (2016)
HOSPITALIZATION BURDEN OF DIASTOLIC HEART FAILURE IN THE UNITED STATES: 2007-2012
Authors: Sagar Mallikethi-Reddy, Fayez Siddiqui, Alexandros Briasoulis, Naveen Trehan, Said Ashraf, Anupama Kottam, Shaun Cardozo, Luis Afonso, Melvyn Rubenfire, Cindy Grines
Journal: Journal of the American College of Cardiology (2017)
Neutrophil Engraftment and Graft-Versus-Host Disease in Elderly Patients Undergoing Hematopoietic Stem Cell Transplantation: Importance of Body Composition Assessment and Geriatric
Authors: Ludmila Koch, Reynaldo Filho, Nelson Hamerschlak, Adham Castro, Adriano Tachibana, Cinthya Silva, Andrea Z Pereira
Journal: Blood (2016)
<i>LRIG1</i> amplification in breast cancer
Authors: I. Ljuslinder, B. Malmer, M. Thomasson, I. Golovleva, K. Grankvist, T. Höckenström, S. Emdin, Y. Jonsson, H. Hedman, R. Henriksson
Journal: Journal of Clinical Oncology (2004)

9627 Background: This study was conducted to investigate if the previously described human gene LRIG1 is of interest in the malignant process of breast cancer. The gene is the human homologue of mouse Lig-1 and is located on chromosome band 3p14.3, a region frequently deleted in human cancers and previous studies of 3p have implicated that a tumour suppressor gene might be located in the area. This gene encodes a transmembrane cell surface protein with extracellular leucine-rich repeats and immunoglobulin–like regions. LRIG1 mRNA and protein has been detected in various tissues, with average levels in breast tissue. Methods: The present study was to characterize the expression of LRIG1 in breast cancer by FISH, CGH, quantitative RT-PCR, Western Blot and immunohistochemistry. Two subgroups were analysed; one group consists of randomly taken tumour samples from 19 patients collected 1987–1995 and the other group included consecutively samples of tumours from 9 patients with parallel sampled non-neoplastic breast tissues for comparison Results: Amplification of LRIG1 was found in 11 of 28 (39%) of tumours, resulting in an overexpression of mRNA and protein. The amplification correlated with increased levels of mRNA and protein by RT-PCR and Western blot. Conclusions: Amplification of LRIG1 in chromosome 3p14.3 is a novel observation indicating a role of LRIG1 in breast cancer. No significant financial relationships to disclose.
IN VIVO CORRELATION OF CAROTID TEMPERATURES AND PET/FDG UPTAKE IN PATIENTS UNDERGOING CAROTID ENDARTERECTOMY: VALIDATION WITH HISTOLOGY
Authors: Georgios Benetos, Konstantinos Toutouzas, Iosif Koutagiar, Alexandros Georgakopoulos, Nikoletta Pianou, Sofoklis Trachanellis, Nikolaos Patelis, George Agrogiannis, Nikolaos Bessias, Konstantinos Filis, Chris Clonaris, George Spyrou, Efstratios Patsouris
Journal: Journal of the American College of Cardiology (2017)
PROTEINURIA IN PATIENTS RECEIVING LEFT VENTRICULAR ASSIST DEVICES IS HIGHLY ASSOCIATED WITH RENAL FAILURE AND MORTALITY
Authors: Rahat Muslem, Kadir Caliskan, Sakir Akin, Dennis A. Hesselink, Glenn Whitman, Ryan Tedford, Ad J.J.C. Bogers, Olivier Manintveld, Stuart Russell
Journal: Journal of the American College of Cardiology (2017)